Tislelizumab,Sorafenib
BeiGene,bayer,novartis
['tislelizumab', 'beigene']
beigene announces data presentations at esmo 2022 including late-breaking oral presentation for tislelizumab in first-line unresectable hepatocellular cancer #stocksmarket #pressrelease
Stock Market News and Press Releases. #StockMarket & #Crypto